These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32734441)

  • 1. A personalised screening strategy for diabetic retinopathy: a cost-effectiveness perspective.
    Emamipour S; van der Heijden AAWA; Nijpels G; Elders P; Beulens JWJ; Postma MJ; van Boven JFM; Feenstra TL
    Diabetologia; 2020 Nov; 63(11):2452-2461. PubMed ID: 32734441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy.
    van der Heijden AA; Walraven I; van 't Riet E; Aspelund T; Lund SH; Elders P; Polak BC; Moll AC; Keunen JE; Dekker JM; Nijpels G
    Diabetologia; 2014 Jul; 57(7):1332-8. PubMed ID: 24763851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening.
    Scanlon PH; Aldington SJ; Leal J; Luengo-Fernandez R; Oke J; Sivaprasad S; Gazis A; Stratton IM
    Health Technol Assess; 2015 Sep; 19(74):1-116. PubMed ID: 26384314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and cost-effectiveness of individualised screening for diabetic retinopathy: the ISDR open-label, equivalence RCT.
    Broadbent DM; Wang A; Cheyne CP; James M; Lathe J; Stratton IM; Roberts J; Moitt T; Vora JP; Gabbay M; García-Fiñana M; Harding SP;
    Diabetologia; 2021 Jan; 64(1):56-69. PubMed ID: 33146763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a model for the prediction of retinopathy in persons with type 1 diabetes.
    Schreur V; Ng H; Nijpels G; Stefánsson E; Tack CJ; Klevering BJ; de Jong EK; Hoyng CB; Keunen JEE; van der Heijden AA
    Br J Ophthalmol; 2021 Sep; 105(9):1286-1288. PubMed ID: 30824420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy.
    Aspelund T; Thornórisdóttir O; Olafsdottir E; Gudmundsdottir A; Einarsdóttir AB; Mehlsen J; Einarsson S; Pálsson O; Einarsson G; Bek T; Stefánsson E
    Diabetologia; 2011 Oct; 54(10):2525-32. PubMed ID: 21792613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland.
    Scotland G; McKeigue P; Philip S; Leese GP; Olson JA; Looker HC; Colhoun HM; Javanbakht M
    Diabet Med; 2016 Jul; 33(7):886-95. PubMed ID: 27040994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study.
    Xie Y; Nguyen QD; Hamzah H; Lim G; Bellemo V; Gunasekeran DV; Yip MYT; Qi Lee X; Hsu W; Li Lee M; Tan CS; Tym Wong H; Lamoureux EL; Tan GSW; Wong TY; Finkelstein EA; Ting DSW
    Lancet Digit Health; 2020 May; 2(5):e240-e249. PubMed ID: 33328056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for diabetic retinopathy: new perspectives and challenges.
    Vujosevic S; Aldington SJ; Silva P; Hernández C; Scanlon P; Peto T; Simó R
    Lancet Diabetes Endocrinol; 2020 Apr; 8(4):337-347. PubMed ID: 32113513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualised screening for diabetic retinopathy: the ISDR study-rationale, design and methodology for a randomised controlled trial comparing annual and individualised risk-based variable-interval screening.
    Broadbent DM; Sampson CJ; Wang A; Howard L; Williams AE; Howlin SU; Appelbe D; Moitt T; Cheyne CP; Rahni MM; Kelly J; Collins J; García-Fiñana M; Stratton IM; James M; Harding SP;
    BMJ Open; 2019 Jun; 9(6):e025788. PubMed ID: 31213445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of a National Telemedicine Diabetic Retinopathy Screening Program in Singapore.
    Nguyen HV; Tan GS; Tapp RJ; Mital S; Ting DS; Wong HT; Tan CS; Laude A; Tai ES; Tan NC; Finkelstein EA; Wong TY; Lamoureux EL
    Ophthalmology; 2016 Dec; 123(12):2571-2580. PubMed ID: 27726962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs.
    Lund SH; Aspelund T; Kirby P; Russell G; Einarsson S; Palsson O; Stefánsson E
    Br J Ophthalmol; 2016 May; 100(5):683-7. PubMed ID: 26377413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incremental cost-effectiveness of screening and laser treatment for diabetic retinopathy and macular edema in Malawi.
    Vetrini D; Kiire CA; Burgess PI; Harding SP; Kayange PC; Kalua K; Msukwa G; Beare NAV; Madan J
    PLoS One; 2018; 13(1):e0190742. PubMed ID: 29300755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to Screen for Diabetic Retinopathy in Chinese Patients with Newly Diagnosed Type 2 Diabetes: A Cost-Effectiveness Analysis.
    Wu B; Li J; Wu H
    Medicine (Baltimore); 2015 Nov; 94(45):e1989. PubMed ID: 26559285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An observational study to assess if automated diabetic retinopathy image assessment software can replace one or more steps of manual imaging grading and to determine their cost-effectiveness.
    Tufail A; Kapetanakis VV; Salas-Vega S; Egan C; Rudisill C; Owen CG; Lee A; Louw V; Anderson J; Liew G; Bolter L; Bailey C; Sadda S; Taylor P; Rudnicka AR
    Health Technol Assess; 2016 Dec; 20(92):1-72. PubMed ID: 27981917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Autonomous Point-of-Care Diabetic Retinopathy Screening for Pediatric Patients With Diabetes.
    Wolf RM; Channa R; Abramoff MD; Lehmann HP
    JAMA Ophthalmol; 2020 Oct; 138(10):1063-1069. PubMed ID: 32880616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-utility of telemedicine to screen for diabetic retinopathy in India.
    Rachapelle S; Legood R; Alavi Y; Lindfield R; Sharma T; Kuper H; Polack S
    Ophthalmology; 2013 Mar; 120(3):566-573. PubMed ID: 23211635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction models for development of retinopathy in people with type 2 diabetes: systematic review and external validation in a Dutch primary care setting.
    van der Heijden AA; Nijpels G; Badloe F; Lovejoy HL; Peelen LM; Feenstra TL; Moons KGM; Slieker RC; Herings RMC; Elders PJM; Beulens JW
    Diabetologia; 2020 Jun; 63(6):1110-1119. PubMed ID: 32246157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualised variable-interval risk-based screening for sight-threatening diabetic retinopathy: the Liverpool Risk Calculation Engine.
    Eleuteri A; Fisher AC; Broadbent DM; García-Fiñana M; Cheyne CP; Wang A; Stratton IM; Gabbay M; Seddon D; Harding SP;
    Diabetologia; 2017 Nov; 60(11):2174-2182. PubMed ID: 28840258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.
    Critselis E; Vlahou A; Stel VS; Morton RL
    Nephrol Dial Transplant; 2018 Mar; 33(3):441-449. PubMed ID: 29106632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.